Clinical Trial Detail

NCT ID NCT02890069
Title A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

non-small cell lung carcinoma

triple-receptor negative breast cancer

Therapies

PDR001 + LCL161

PDR001 + Everolimus

PDR001 + Panobinostat

Age Groups: adult senior

No variant requirements are available.